Expression of phosphorylated extracellular signal-regulated kinase at the invasive front of hepatic colorectal metastasis

Hyun Soo Kim, Sung Im Do, Byeong Joo Noh, Young In Jeong, Sun Jin Park, Youn Wha Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Raf-1 kinase inhibitory protein (RKIP), an endogenous inhibitor of the extracellular signal-regulated kinase (ERK) pathway, suppresses metastasis in a number of cancer types, including colorectal carcinoma (CRC); thus, RKIP downregulation significantly contributes to CRC invasiveness and metastatic potential. However, our previous study demonstrated that RKIP-positive tumors in CRC patients are predictive of hepatic colorectal metastases (HCMs). Based on the previous finding that the ERK pathway can be activated independently of RKIP, we hypothesized that RKIP-expressing HCMs may express significant levels of phosphorylated ERK (pERK). Thus, the present study evaluated the expression of RKIP and pERK in 68 HCM tissue samples using immunohistochemistry. RKIP expression was positive in 22 (32.4%) of the 68 samples, seven (31.8%) of which exhibited nuclear pERK immunoreactivity exclusively at the invasive tumor front. Furthermore, pERK expression at the invasive front was significantly associated with recurrent HCM following hepatic resection, and pERK expression observed at the invasive front of RKIP-expressing HCMs indicated that the activation of the ERK pathway may also be involved in the invasive process of these tumors, despite the presence of RKIP. A strong association between pERK expression and the presence of recurrent HCM may indicate that the ERK pathway is important in the metastatic recurrence of RKIP-positive HCM.

Original languageEnglish
Pages (from-to)1261-1265
Number of pages5
JournalOncology Letters
Volume9
Issue number3
DOIs
Publication statusPublished - 2015 Mar 1

Fingerprint

Proto-Oncogene Proteins c-raf
Extracellular Signal-Regulated MAP Kinases
Neoplasm Metastasis
Liver
Proteins
Colorectal Neoplasms
Neoplasms
Down-Regulation
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Hyun Soo ; Do, Sung Im ; Noh, Byeong Joo ; Jeong, Young In ; Park, Sun Jin ; Kim, Youn Wha. / Expression of phosphorylated extracellular signal-regulated kinase at the invasive front of hepatic colorectal metastasis. In: Oncology Letters. 2015 ; Vol. 9, No. 3. pp. 1261-1265.
@article{a95ad2ed82f646e09592f93ddd238665,
title = "Expression of phosphorylated extracellular signal-regulated kinase at the invasive front of hepatic colorectal metastasis",
abstract = "Raf-1 kinase inhibitory protein (RKIP), an endogenous inhibitor of the extracellular signal-regulated kinase (ERK) pathway, suppresses metastasis in a number of cancer types, including colorectal carcinoma (CRC); thus, RKIP downregulation significantly contributes to CRC invasiveness and metastatic potential. However, our previous study demonstrated that RKIP-positive tumors in CRC patients are predictive of hepatic colorectal metastases (HCMs). Based on the previous finding that the ERK pathway can be activated independently of RKIP, we hypothesized that RKIP-expressing HCMs may express significant levels of phosphorylated ERK (pERK). Thus, the present study evaluated the expression of RKIP and pERK in 68 HCM tissue samples using immunohistochemistry. RKIP expression was positive in 22 (32.4{\%}) of the 68 samples, seven (31.8{\%}) of which exhibited nuclear pERK immunoreactivity exclusively at the invasive tumor front. Furthermore, pERK expression at the invasive front was significantly associated with recurrent HCM following hepatic resection, and pERK expression observed at the invasive front of RKIP-expressing HCMs indicated that the activation of the ERK pathway may also be involved in the invasive process of these tumors, despite the presence of RKIP. A strong association between pERK expression and the presence of recurrent HCM may indicate that the ERK pathway is important in the metastatic recurrence of RKIP-positive HCM.",
author = "Kim, {Hyun Soo} and Do, {Sung Im} and Noh, {Byeong Joo} and Jeong, {Young In} and Park, {Sun Jin} and Kim, {Youn Wha}",
year = "2015",
month = "3",
day = "1",
doi = "10.3892/ol.2015.2874",
language = "English",
volume = "9",
pages = "1261--1265",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

Expression of phosphorylated extracellular signal-regulated kinase at the invasive front of hepatic colorectal metastasis. / Kim, Hyun Soo; Do, Sung Im; Noh, Byeong Joo; Jeong, Young In; Park, Sun Jin; Kim, Youn Wha.

In: Oncology Letters, Vol. 9, No. 3, 01.03.2015, p. 1261-1265.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of phosphorylated extracellular signal-regulated kinase at the invasive front of hepatic colorectal metastasis

AU - Kim, Hyun Soo

AU - Do, Sung Im

AU - Noh, Byeong Joo

AU - Jeong, Young In

AU - Park, Sun Jin

AU - Kim, Youn Wha

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Raf-1 kinase inhibitory protein (RKIP), an endogenous inhibitor of the extracellular signal-regulated kinase (ERK) pathway, suppresses metastasis in a number of cancer types, including colorectal carcinoma (CRC); thus, RKIP downregulation significantly contributes to CRC invasiveness and metastatic potential. However, our previous study demonstrated that RKIP-positive tumors in CRC patients are predictive of hepatic colorectal metastases (HCMs). Based on the previous finding that the ERK pathway can be activated independently of RKIP, we hypothesized that RKIP-expressing HCMs may express significant levels of phosphorylated ERK (pERK). Thus, the present study evaluated the expression of RKIP and pERK in 68 HCM tissue samples using immunohistochemistry. RKIP expression was positive in 22 (32.4%) of the 68 samples, seven (31.8%) of which exhibited nuclear pERK immunoreactivity exclusively at the invasive tumor front. Furthermore, pERK expression at the invasive front was significantly associated with recurrent HCM following hepatic resection, and pERK expression observed at the invasive front of RKIP-expressing HCMs indicated that the activation of the ERK pathway may also be involved in the invasive process of these tumors, despite the presence of RKIP. A strong association between pERK expression and the presence of recurrent HCM may indicate that the ERK pathway is important in the metastatic recurrence of RKIP-positive HCM.

AB - Raf-1 kinase inhibitory protein (RKIP), an endogenous inhibitor of the extracellular signal-regulated kinase (ERK) pathway, suppresses metastasis in a number of cancer types, including colorectal carcinoma (CRC); thus, RKIP downregulation significantly contributes to CRC invasiveness and metastatic potential. However, our previous study demonstrated that RKIP-positive tumors in CRC patients are predictive of hepatic colorectal metastases (HCMs). Based on the previous finding that the ERK pathway can be activated independently of RKIP, we hypothesized that RKIP-expressing HCMs may express significant levels of phosphorylated ERK (pERK). Thus, the present study evaluated the expression of RKIP and pERK in 68 HCM tissue samples using immunohistochemistry. RKIP expression was positive in 22 (32.4%) of the 68 samples, seven (31.8%) of which exhibited nuclear pERK immunoreactivity exclusively at the invasive tumor front. Furthermore, pERK expression at the invasive front was significantly associated with recurrent HCM following hepatic resection, and pERK expression observed at the invasive front of RKIP-expressing HCMs indicated that the activation of the ERK pathway may also be involved in the invasive process of these tumors, despite the presence of RKIP. A strong association between pERK expression and the presence of recurrent HCM may indicate that the ERK pathway is important in the metastatic recurrence of RKIP-positive HCM.

UR - http://www.scopus.com/inward/record.url?scp=84921763484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921763484&partnerID=8YFLogxK

U2 - 10.3892/ol.2015.2874

DO - 10.3892/ol.2015.2874

M3 - Article

AN - SCOPUS:84921763484

VL - 9

SP - 1261

EP - 1265

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -